【私募调研记录】神农投资调研科兴制药、萤石网络等3只个股（附名单）

Group 1: Key Insights on Companies - Kexing Pharmaceutical has a clear innovation drug development pipeline strategy, transitioning from fast-follow monoclonal antibodies to dual-target or tri-target antibodies from 2022 to 2023, and planning to focus on FIC tri-target antibodies starting in 2024 [1] - The company expects to complete some business development collaborations for its R&D pipeline by 2025, with a focus on overseas partnerships from PCC to IND stages [1] - The GB18 project aims to improve weight loss and enhance muscle and fat weight, with domestic IND accepted and US IND application in progress [1] - The company anticipates a foreign sales revenue growth target of 200%-400%, leveraging its overseas commercialization platform for long-term business growth [1] Group 2: Key Insights on Industry Trends - Yingzi Network has made significant progress in smart home cameras and cloud services, with smart home becoming a second growth curve and profitability gradually improving [2] - The company is expanding its AI cloud services and has introduced new products targeting young users and outdoor sports markets [2] - Despite the downturn in real estate, the company’s pre-installation business is less affected, focusing mainly on post-installation sales [2] Group 3: Key Insights on Technology Sector - Lanke Technology will focus on the development of computing power chips for intelligent hardware over the next 5-10 years, emphasizing the importance of interconnect chips [3] - The demand for DDR5 memory interface chips is expected to rise significantly due to AI industry trends, with the second generation of MRDIMM likely becoming a preferred solution for high-performance computing and AI applications [3] - The company plans to continue advancing its memory interface chips, PCIe Retimer, and MXC chips, while also exploring the PCIe Switch and optical interconnect fields [3]